Nyxoah has appointed Liam Kelly as its chief executive officer, effective October 1, succeeding Olivier Taelman after seven years of leadership. The company’s release carried by GlobeNewswire confirms the handoff, and Belgian business daily L’Echo frames Kelly’s task around establishing the Genio system in the U.S. market.
A commercial handoff at Nyxoah
Taelman led Nyxoah through a sequence the company describes as a move from clinical development to U.S. market entry, including FDA approval for Genio. The board credited him with guiding the company over seven years and thanked him for taking it through those milestones. Kelly arrives as the company describes itself as moving into a more commercial phase, with its attention increasingly fixed on the United States.
Kelly brings more than 25 years of executive experience in medical technology. He was chairman, president and CEO of Teleflex until January 2026, having joined that company in 2009 and held senior operational roles across EMEA, international markets and the Americas before becoming chief operating officer and then CEO. He currently serves as a director of Enovis. The company’s announcement presents this background as relevant to expanding Nyxoah’s commercial organization and U.S. presence.
Genio becomes the central assignment
L’Echo describes the near-term challenge as bringing Genio, Nyxoah’s treatment for obstructive sleep apnea, to more U.S. patients. The company says that FDA approval and the system’s U.S. introduction mark a shift from development toward commercial execution. Kelly said he intends to draw on experience building and scaling global operations as he works with the Nyxoah team.
The handover gives the new CEO a defined starting point and date: October 1, with Taelman’s seven-year period at the helm ending as the business enters its U.S. rollout. Nyxoah has not announced additional organizational changes in the release. For readers following leadership in medical technology, the appointment sits alongside Hikma’s recent CFO succession, another executive transition at a healthcare company.